Pudil, R. Mueller, C. Čelutkienė, J. Henriksen, P.A. Lenihan, D. Dent, S. Barac, A. Stanway, S. Moslehi, J. Suter, T.M. Ky, B. Štěrba, M. Cardinale, D. Cohen-Solal, A. Tocchetti, C.G. Farmakis, D. Bergler-Klein, J. Anker, M.S. Von Haehling, S. Belenkov, Y. Iakobishvili, Z. Maack, C. Ciardiello, F. Ruschitzka, F. Coats, A.J.S. Seferovic, P. Lainscak, M. Piepoli, M.F. Chioncel, O. Bax, J. Hulot, J.-S. Skouri, H. Hägler-Laube, E.S. Asteggiano, R. Fernandez, T.L. de Boer, R.A. Lyon, A.R., Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology, European Journal of Heart Failure, (22), 1966-1983, 2020, John Wiley and Sons Ltd,